
|Articles|May 1, 2003
Allergan begins launch of cyclosporine
Irvine, CA-In early April, cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) became commercially available for the treatment of eye inflammation associated with keratoconjunctivitis sicca. The introduction of the product marks the first therapeutic option for people with dry eye by not only providing temporary relief of dry eye, but also treating the associated ocular inflammation, according to the company.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: Optimizing the ocular surface for light adjustable lens technology
2
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
3
PRIMA System: A major step in the battle against GA
4
Angiogenesis 2026: Continuous AI severity scoring could transform AMD monitoring
5




























